Study Evaluating Vabicaserin in Subjects With Schizophrenia
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability
of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of
schizophrenia.